Expert Review of Vaccines最新文献_第3页

Global status of HPV vaccination two decades in: effective, safe and preventing cancer. 二十年来HPV疫苗接种的全球现状：有效、安全和预防癌症。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2025-12-30 DOI: 10.1080/14760584.2025.2609869

Julia M L Brotherton, D Scott LaMontagne, Paul J N Bloem

{"title":"Global status of HPV vaccination two decades in: effective, safe and preventing cancer.","authors":"Julia M L Brotherton, D Scott LaMontagne, Paul J N Bloem","doi":"10.1080/14760584.2025.2609869","DOIUrl":"10.1080/14760584.2025.2609869","url":null,"abstract":"Introduction: Prophylactic human papillomavirus vaccines have been in use in populations worldwide for nearly 20 years. Much has been learnt in relation to their effectiveness, safety, and how best to effectively implement them in populations to prevent cancer and other HPV-related diseases. Global challenges such as limited supply and the mismatch between those who can afford them and those with the greatest disease burden from cervical cancer have prevented optimal usage to date.Areas covered: Here we identified recent papers and focus upon the accumulated evidence regarding HPV vaccine: i) effectiveness in preventing cancer and precancerous lesions, ii) safety in population usage, iii) trial evidence supporting registration of four newer vaccines, iv) progress in country-level introductions and coverage, and v) lessons learned in effective implementation.Expert opinion: Reasons for optimism are many, with vast cumulative knowledge on impact, safety and implementation and accelerating HPV vaccine introductions, simplification of delivery and reduced costs through single dose approaches and supply constraints easing. However, considerable challenges remain in achieving and maintaining high and equitable global coverage, given the uncertainty in funding, risk to ongoing prioritization of health equity and to vaccine confidence in the current global public health environment.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2609869"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China. 中国带状疱疹减毒活疫苗安全性的自我对照病例系列研究。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-07 DOI: 10.1080/14760584.2026.2626926

Xiang Cao, Mingwei Wei, Xiang Huo, Yuanbao Liu, Ming Xu, Xiaoshan Wang, Xianzhang Huang, Hui Ma, Na Xu, Qiang Lu, Shihua Ma, Pengfei Jin, Jingxin Li

{"title":"A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China.","authors":"Xiang Cao, Mingwei Wei, Xiang Huo, Yuanbao Liu, Ming Xu, Xiaoshan Wang, Xianzhang Huang, Hui Ma, Na Xu, Qiang Lu, Shihua Ma, Pengfei Jin, Jingxin Li","doi":"10.1080/14760584.2026.2626926","DOIUrl":"10.1080/14760584.2026.2626926","url":null,"abstract":"Background: Herpes zoster (HZ), caused by varicella-zoster virus, primarily affects the elderly. In May 2023, the first domestically produced live attenuated zoster vaccine was approved for use in adults aged 40 years or older in China.Research design and methods: We conducted a self-controlled case series study to collect hospitalization events among 25,000 vaccinated adults (April 2020-December 2023, 5 regions) during the risk period (0-42 days) and the control period (72-162 days). Conditional Poisson regression models and conditional logistic regression models were applied to compare the risk of hospitalization.Results: The rate ratio of hospitalization following immunization was 0·381 (0·323-0·450). Compared with those in control period, the incidence rates of the following hospitalization events decreased: RRs of 0·297 (0·203-0·435) for stroke, cerebrovascular, and nervous system diseases; 0·296 (0·205-0·527) for cardiovascular diseases; 0·183 (0·054-0·627) for genitourinary system diseases; 0·246 (0·155-0·391) for respiratory, thoracic, and mediastinal diseases; 0·238 (0·089-0·635) for diseases of eye and adnexal diseases; and 0·202 (0·053-0·766) for skin and subcutaneous tissue diseases.Conclusions: This study confirms the safety of the live attenuated zoster vaccine, demonstrating that vaccination does not increase the risk of hospitalization and may even reduce the incidence of hospitalization.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626926"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study. 肺炎球菌疫苗接种对患有炎症性肠病的儿童和青少年疾病活动性的影响：一项为期2年的前瞻性研究

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-30 DOI: 10.1080/14760584.2026.2652921

Magdalena Neścioruk, Kinga Kowalska-Duplaga, Urszula Grzybowska-Chlebowczyk, Agnieszka Sieczkowska, Aleksandra Banaszkiewicz

{"title":"The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study.","authors":"Magdalena Neścioruk, Kinga Kowalska-Duplaga, Urszula Grzybowska-Chlebowczyk, Agnieszka Sieczkowska, Aleksandra Banaszkiewicz","doi":"10.1080/14760584.2026.2652921","DOIUrl":"10.1080/14760584.2026.2652921","url":null,"abstract":"Background: Infectious diseases are known triggers for inflammatory bowel disease (IBD) exacerbations. Although vaccines can prevent many such infections, hesitancy persists among pediatric IBD patients and their caregivers due to concerns about vaccine-induced disease flare-ups. The aim of the study was to evaluate the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on disease activity in children and adolescents with IBD over a 24-month period post-vaccination.Research design and methods: This prospective, multicenter cohort study included IBD patients aged 4-18 years. Participants were assigned to a vaccinated group (single PCV13 dose) or an unvaccinated control group. Disease activity was monitored using PUCAI/PCDAI scores, and exacerbation rates were recorded at 6, 12, 18, and 24 months.Results: A total of 279 patients (52.3% male; median age, 167 months) were enrolled, of whom 93 (33.3%) received PCV13. The control group showed higher, but not statistically significant, disease activity at any time point (p = 0.06, 0.10, 0.64, 0.36) and exacerbation rates (p = 0.47, 0.17, 0.82, 0.75).Conclusion: A single dose of PCV13 does not increase disease activity in pediatric IBD patients during the 24 months following vaccination.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2652921"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development. 呼吸道病毒的新型疫苗平台：已获许可的疫苗和处于后期开发阶段的候选疫苗综述

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-05 DOI: 10.1080/14760584.2026.2667742

Sabiha R Hussain, Hana M El Sahly

{"title":"Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development.","authors":"Sabiha R Hussain, Hana M El Sahly","doi":"10.1080/14760584.2026.2667742","DOIUrl":"10.1080/14760584.2026.2667742","url":null,"abstract":"Introduction: Respiratory infections with influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 are a major cause of global mortality. Vaccination is a cornerstone of disease prevention, though traditional platforms face challenges. Recently, several vaccines utilizing mRNA and adenovirus platforms were brought to the market, with additional vaccines undergoing Phase 3 clinical testing.Areas covered: This review assesses vaccine literature primarily from 2020 to the present, using National Library of Medicine databases. The rapidity of mRNA technology was tested and implemented successfully during the COVID-19 pandemic. Since then, the mRNA RSV vaccine has been licensed as well. mRNA platforms also offer the ability of combining antigens for multivalent vaccines against multiple pathogens. Several combination products have been used in phase III clinical trials. Adenovirus-vectored vaccines for respiratory viruses have the added advantage of mucosal-based delivery and inducing a potentially stronger local immune response. However, both of these platforms have immunogenicity and safety shortcomings.Expert opinion: Novel respiratory virus vaccine platforms have demonstrated their importance with both endemic and pandemic pathogens, because of decades of concerted efforts and investment in research. Expediting future vaccine development requires a continuation of these efforts with a focus on pre-clinical models and a better understanding of correlates of protection.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2667742"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the development of a vaccine to target meningococcal serogroup X. 针对脑膜炎球菌血清群X的疫苗开发的最新进展。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-28 DOI: 10.1080/14760584.2026.2707148

Kelly Townsend-Payne, Jennifer Louth, Ray Borrow, Stephen A Clark

{"title":"Recent advances in the development of a vaccine to target meningococcal serogroup X.","authors":"Kelly Townsend-Payne, Jennifer Louth, Ray Borrow, Stephen A Clark","doi":"10.1080/14760584.2026.2707148","DOIUrl":"10.1080/14760584.2026.2707148","url":null,"abstract":"Introduction: Serogroup X has emerged as an important cause of invasive meningococcal disease across Sub-Saharan Africa. Recent advances in serogroup X vaccines were reviewed.Areas covered: Early vaccine development efforts focused on outer membrane vesicle-based approaches. The growing epidemiological importance of serogroup X accelerated the development of serogroup X conjugate vaccines. Building on the success of MenAfriVac, PATH and the Serum Institute of India Pvt. Ltd. developed NmCV-5 (MenFive), the first pentavalent meningococcal conjugate vaccine targeting serogroup X. NmCV-5 achieved World Health Organization (WHO) pre-qualification in 2023, enabling deployment across Sub-Saharan Africa. A second pentavalent vaccine, EuNmCV-5, developed by Eubiologics is advancing through clinical development, while an additional candidate from Sinovac Biotech is entering early phase evaluation. These advances representative a major milestone in meningococcal disease prevention.Expert opinion: Within the last fifteen years significant vaccine developments have been made to combat serogroup X. With NmCV-5 attaining WHO pre-qualification, strategies for its implementation within Sub-Saharan Africa are being devised. Only one vaccine is currently available in Sub- Saharan Africa, but trials of a second pentavalent ACWYX conjugate vaccine are ongoing. Carriage studies and disease surveillance are crucial to monitor serogroup X vaccine effectiveness.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2707148"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of immunogenicity, safety, and efficacy of EVA71 vaccine in children: a systematic review and meta-analysis. 儿童EVA71疫苗免疫原性、安全性和有效性的比较：系统回顾和荟萃分析

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-08-25 DOI: 10.1080/14760584.2026.2722426

Muhammad Gilang Dwi Putra, Rodman Tarigan Girsang, Rais Amaral Haq, Teuku Fais Duta, Frengki Prabowo Saputro Wijayanto, Artha Maressa Theodora Simanjuntak, Eddy Fadlyana, Kusnandi Rusmil

{"title":"Comparison of immunogenicity, safety, and efficacy of EVA71 vaccine in children: a systematic review and meta-analysis.","authors":"Muhammad Gilang Dwi Putra, Rodman Tarigan Girsang, Rais Amaral Haq, Teuku Fais Duta, Frengki Prabowo Saputro Wijayanto, Artha Maressa Theodora Simanjuntak, Eddy Fadlyana, Kusnandi Rusmil","doi":"10.1080/14760584.2026.2722426","DOIUrl":"10.1080/14760584.2026.2722426","url":null,"abstract":"Introduction: Enterovirus 71 (EV-A71) is a principal cause of hand, foot, and mouth disease (HFMD), potentially leading to severe neurological complications in children. Inactivated EV-A71 vaccines have been introduced. This study compares the immunogenicity, safety, and efficacy of EV-A71 vaccines versus placebo in pediatric populations.Research design and methods: Following a PROSPERO-registered protocol, RCTs involving EV-A71 in children were identified via PubMed, Scopus, Cochrane, and ClinicalTrials.gov. Two independent reviewers performed screening, extraction, and RoB assessments (RoB 2.0).Results: Five phase III RCTs involving 36,659 children were included. EV-A71 vaccination significantly increased seropositivity across follow-up periods, including early (RR 5.8), medium-term (RR 3.09), and long-term (RR 2.95) response. Seroconversion was significantly higher in the vaccinated group (pooled RR 13.04, 95% CI 2.80-60.61; p < 0.001). Geometric mean titers, analyzed using the ratio of means approach, were significantly higher in the vaccinated group during early and medium-term follow-up. Vaccine efficacy against EV-A71-associated HFMD exceeded 98% (pooled RR 0.02, 95% CI 0.01-0.09; p = 0.0028; I2 = 50%). Solicited local and systemic adverse events were mild and comparable between groups.Conclusion: Inactivated EV-A71 vaccines robust immunogenicity, high clinical efficacy, and an acceptable safety profile in children. Future studies should explore long-term protection, booster schedules, and multivalent formulations against non-EV-A71 serotypes.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2722426"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). mRNA SARS-CoV-2疫苗接种与COVID-19急性后后遗症（PASC）患者疲劳和功能恢复的关系

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-17 DOI: 10.1080/14760584.2026.2735166

Philipp Pries, Jan Fuge, Michele Scharbau, Lennart Boblitz, Andrea Sauer, Nora Drick, Benjamin-Alexander Bollmann, Jannik Ruwisch, Marius M Hoeper, Isabell Pink

{"title":"Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC).","authors":"Philipp Pries, Jan Fuge, Michele Scharbau, Lennart Boblitz, Andrea Sauer, Nora Drick, Benjamin-Alexander Bollmann, Jannik Ruwisch, Marius M Hoeper, Isabell Pink","doi":"10.1080/14760584.2026.2735166","DOIUrl":"10.1080/14760584.2026.2735166","url":null,"abstract":"Background: Patients with post-acute sequelae of SARS-CoV-2 (PASC) fear SARS-CoV-2 vaccine-linked symptom aggravation. Data on objective functional outcomes are limited.Methods: We performed a retrospective analysis of an observational cohort at a post-COVID outpatient clinic at Hannover Medical School with standardized assessments at baseline and follow-up visit (3-6 months) in adults with confirmed SARS-CoV-2 infection and PASC. Participants were classified as vaccination (receipt of an additional SARS-CoV-2 vaccine dose between visits) or no vaccination. Primary outcomes were fatigue (Fatigue Assessment Scale) and exercise capacity (6-minute walk distance). Propensity scores matching (1:1 nearest-neighbor, ATT; caliper 0.2 SD) was performed using logistic regression. Group differences were assessed using t-tests/χ2 tests with Benjamini-Hochberg adjustment. Longitudinal changes were analyzed using linear mixed-effects models.Results: Of 193 eligible patients, 174 were analyzed, 148 remained after matching (74 per group). No significant differences between the groups were observed at baseline or follow-up after adjustment for multiple comparisons. Both groups improved over time, with no statistically significant difference in fatigue or exercise capacity.Conclusions: Fatigue and functional performance improved over time regardless of vaccination status. We found no statistically significant association between mRNA SARS-CoV-2 vaccination and worsening symptoms or impaired recovery, although smaller effects cannot be excluded.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2735166"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing RSV infection in older adults: implications for public health policy. 处理老年人呼吸道合胞病毒感染：对公共卫生政策的影响

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-15 DOI: 10.1080/14760584.2026.2644348

Floriana D'Ambrosio, Marta Lomazzi, Michael Moore, Roberto Ricciardi, Sabella Mourino, Walter Ricciardi, Giovanna Elisa Calabrò

{"title":"Addressing RSV infection in older adults: implications for public health policy.","authors":"Floriana D'Ambrosio, Marta Lomazzi, Michael Moore, Roberto Ricciardi, Sabella Mourino, Walter Ricciardi, Giovanna Elisa Calabrò","doi":"10.1080/14760584.2026.2644348","DOIUrl":"10.1080/14760584.2026.2644348","url":null,"abstract":"Background: The aging population increases healthcare challenges, especially in preventing infectious diseases. Respiratory syncytial virus (RSV), historically associated with pediatric illness, is now recognized as a significant cause of severe disease and mortality in older adults. Despite scientific advances, including new RSV vaccines, adult immunization policies across Europe remain fragmented and underdeveloped.Research design and methods: This study, promoted by the World Federation of Public Health Associations (WFPHA), assessed RSV surveillance, vaccination strategies, and capacity-building effort in eight European countries (Bulgaria, Finland, Germany, Italy, Norway, Portugal, Spain, and Serbia). A structured questionnaire, informed by a preliminary literature review, was administered to a panel of 19 experts, with a 79% (15/19) response rate.Results: Findings revealed marked heterogeneity and persistent gaps across countries, including fragmented RSV surveillance, limited or missing vaccine recommendations for older adults, lack of age-specific monitoring, and insufficient training and communication initiatives for healthcare providers and the public.Conclusion: To address these issues, the expert panel proposed policy recommendations to improve surveillance, ensure equitable vaccine access, and enhance professional training and awareness, providing a roadmap for stronger, prevention-focused healthcare across Europe.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2644348"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When precision medicine meets rigid vaccination: bridging the policy gap for patients on biologics. 当精准医学遇到严格的疫苗接种：弥合患者对生物制剂的政策差距。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-26 DOI: 10.1080/14760584.2026.2708198

Dingxian He, Yunlu Zhang, Sushan Luo, Tianxing Feng

引用次数: 0

Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance. 预防新生儿败血症的疫苗：重点关注B群链球菌、肺炎克雷伯菌和大肠杆菌，以应对日益严重的抗菌素耐药性。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/14760584.2026.2622690

Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo

{"title":"Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance.","authors":"Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo","doi":"10.1080/14760584.2026.2622690","DOIUrl":"10.1080/14760584.2026.2622690","url":null,"abstract":"Introduction: Neonatal sepsis, a systemic infection occurring in infants within their first 28 days of life, is a leading cause of mortality globally. The burden is especially severe in low- and middle-income countries (LMICs), where incidence and mortality rates are higher than in high-resource settings. Antimicrobial resistance, driven by multidrug-resistant pathogens prevalent in LMICs, further complicates its effective management. Vaccination offers a promising strategy to prevent infections caused by common neonatal sepsis pathogens, potentially reducing sepsis incidence and mitigating resistance.Area covered: This review examines the burden of bacterial pathogens, specifically Group B Streptococcus (GBS), Klebsiella pneumoniae, and Escherichia coli, responsible for neonatal sepsis, drawing from a comprehensive literature search focusing on the last ten years across major databases. It provides an overview of vaccine candidates in clinical development, highlights innovative approaches in preclinical research, and discusses the key challenges associated with vaccine strategies preventing neonatal sepsis.Expert opinion: Given the multivalency of vaccines for neonatal sepsis, innovative technologies are under investigation. Defining correlate of protections has been critical for GBS vaccine development, and may pave the way for vaccines against K. pneumoniae and E. coli. Novel regulatory and clinical strategies, including disease-based rather than pathogen-specific approaches, should be explored.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2622690"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0